Anuh Pharma Ltd

Anuh Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 26 August 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 September 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

After a sustained rally over the past week, Anuh Pharma Ltd surged to a fresh 52-week high of Rs 99.5 on 9 Sep 2026, marking a significant milestone for the micro-cap pharmaceutical player amid a broadly subdued market backdrop.

Surging past its previous peaks, Anuh Pharma Ltd touched a fresh 52-week high of Rs 97 on 8 Sep 2026, marking a significant milestone in its price momentum. This rally comes amid a backdrop of broad technical alignment and sustained gains over the past four sessions.

Anuh Pharma Ltd has demonstrated a significant shift in price momentum, supported by a series of bullish technical indicators and an upgrade in its overall rating. The stock’s recent surge, coupled with positive signals from MACD, Bollinger Bands, and moving averages, suggests growing investor confidence in this micro-cap pharmaceutical player.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 26 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term growth and recent flat quarterly results.

Anuh Pharma Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underpinned by a combination of moving average signals and volume-based indicators, despite some lingering bearishness in longer-term oscillators. Investors and analysts are closely monitoring these developments as the stock attempts to regain upward momentum within the Pharmaceuticals & Biotechnology sector.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, Bollinger Bands, and KST, signal caution for investors as the stock faces downward pressures despite a mildly bullish daily moving average.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day change of 0.13%, the stock’s technical indicators present a complex picture, with some signals suggesting bullish tendencies while others remain bearish, prompting a recent downgrade in its Mojo Grade from Hold to Sell.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Aug 2026. This change reflects a complex interplay of deteriorating technical indicators, modest valuation improvements, flat financial trends, and subdued quality metrics, signalling caution for investors despite some attractive valuation parameters.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a transition from sideways movement to a mildly bearish trend. Recent technical assessments reveal deteriorating momentum on weekly and monthly charts, prompting a downgrade in its Mojo Grade from Hold to Sell as of 17 Aug 2026.

Anuh Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting a subtle but meaningful improvement in price appeal relative to its historical and peer benchmarks. Despite a modest decline in share price, the company’s valuation metrics suggest a recalibration that investors should carefully analyse amid a challenging sector backdrop.

Anuh Pharma Ltd has seen its investment rating upgraded from Sell to Hold as of 11 August 2026, reflecting improvements in valuation and technical indicators despite ongoing challenges in financial performance and long-term growth. The company’s micro-cap status and sector positioning in Pharmaceuticals & Biotechnology remain unchanged, but a detailed analysis across quality, valuation, financial trends, and technicals reveals the rationale behind this shift.

Anuh Pharma Ltd (Stock ID: 905552), a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Recent technical indicators such as MACD, RSI, and moving averages reveal a complex picture of cautious optimism tempered by lingering bearish signals, reflecting the stock’s struggle to gain sustained upward traction amid broader market pressures.

The 50-day moving average has crossed above the 200-day moving average for Anuh Pharma Ltd, signalling a golden cross on 11 Aug 2026. Yet, the stock’s modest 0.21% gain on the day and a patchwork of conflicting technical indicators suggest this crossover is not a straightforward bullish endorsement.

Anuh Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change comes despite recent share price softness and a challenging industry backdrop, prompting a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical levels and peer benchmarks.